Colorectal cancer in patients seen at the teaching hospitals of Guadeloupe and Martinique: discrepancies, similarities in clinicopathological features, and p53 status
1 UMR Inserm_S1134, Université des Antilles et de la Guyane (UAG), CNRS SNC 9169, Pointe-à-Pitre, Guadeloupe
2 Department of Anatomopathology, Teaching Hospital of Zobda Quitman, Fort de France, Martinique, France
3 Department of Anatomopathology, Teaching Hospital of Pointe-à-Pitre, Pointe-à-Pitre, Guadeloupe
4 Centre d’Investigation Clinique-EC Antilles Guyane (CIE 802 Inserm), Teaching Hospital of Pointe-à-Pitre, Pointe-à-Pitre, Guadeloupe
5 Cancer Registry of Martinique (AMREC), Fort de France, Martinique
6 Cancer Registry of Guadeloupe, Teaching Hospital of Pointe-à-Pitre, Pointe-à-Pitre, Guadeloupe
7 Department of Digestive Surgery, Teaching Hospital of Pointe-à-Pitre, Pointe-à-Pitre, Guadeloupe
8 UAG, Département Scientifique Interfacultaire, EA929 AIHP-GEODE BIOSPHERES, Campus de Schœlcher, Martinique 97200, France
9 UMR_S1134 Inserm, CHU de Pointe-à-Pitre, bâtiment Ricou, 97159 Guadeloupe, France
BMC Clinical Pathology 2014, 14:12 doi:10.1186/1472-6890-14-12Published: 29 March 2014
In Guadeloupe and Martinique, two French Overseas Departments, colorectal cancer (CRC) has become an essential public health issue. However, little is known about CRC characteristics and the p53 status in these populations, particularly in Guadeloupe, whereas certification of a cancer registry has been recently validated.
This was a descriptive retrospective study of 201 patients who, between 1995 and 2000, underwent surgery for CRC in the Guadeloupe Teaching Hospital (GlpeTH; 83 patients) and in the Martinique Teaching Hospital (MqueTH; 118 patients). The clinicopathological features and the p53 expression, evaluated with immunohistochemistry, were compared at the time of diagnosis. A relationship between these parameters and the p53 expression was also studied. Data were analysed, using the SPSS computer software version 17.0.
No statistical difference was found between the two groups of patients regarding age (p = 0.60), percentage of young patients (≤50 years; p = 0.94)), sex (p = 0.47), histological type (p = 0.073) and tumour sites (p = 0.65), although the GlpeTH patients were diagnosed with more distal colon cancers (54.2%) than the Mque TH patients (47.4%). By contrast, a significant difference was found regarding the tumour grade (p < 0.0001), the pTNM stage (p = 0.045) and the pT stage (p < 0.0001). Regarding p53 expression, solely for the MqueTH patients, nuclear expression was associated with pTNM, the percentage of p53 negative tumours increasing with the progression of the pTNM stages (p = 0.029).
For the first time, this study reveals discrepancies in clinicopathological features and in the p53 status between the two groups of patients. The GlpeTH patients were diagnosed with more moderated CRCs but with few CRCs at pTNM IV stage. By contrast, the MqueTH patients were diagnosed with more differentiated tumours, but with many more CRCs at pTNM IV stage. This paradox may be due to differences in tumour location (distal vs proximal), multiplicity of the genetic profiles of patients, or patients getting treatment elsewhere. Although our study is limited due to its small size, it emphasizes the originality of our results.